Body Mass Index, Chemotherapy-Related Weight Changes, and Disease-Free Survival in Haitian Women With Nonmetastatic Breast Cancer.

Autor:	Fadelu T; Dana-Farber Cancer Institute, Boston, MA., Damuse R; Hôpital Universitaire de Mirebalais, Mirebalais, Haiti.; Zanmi Lasante, Croix-des-Bouquet, Haiti., Lormil J; Hôpital Universitaire de Mirebalais, Mirebalais, Haiti.; Zanmi Lasante, Croix-des-Bouquet, Haiti., Pecan E; Wharton Business School, University of Pennsylvania, Philadelphia, PA., Greenberg L; Partners In Health, Boston, MA., Dubuisson C; Hôpital Universitaire de Mirebalais, Mirebalais, Haiti.; Zanmi Lasante, Croix-des-Bouquet, Haiti., Pierre V; Hôpital Universitaire de Mirebalais, Mirebalais, Haiti.; Zanmi Lasante, Croix-des-Bouquet, Haiti., Triedman SA; Dana-Farber Cancer Institute, Boston, MA.; The Warren Alpert Medical School of Brown University, Providence, RI., Shulman LN; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Rebbeck TR; Dana-Farber Cancer Institute, Boston, MA.; Harvard T.H. Chan School of Public Health, Boston, MA.
Jazyk:	angličtina
Zdroj:	JCO global oncology [JCO Glob Oncol] 2020 Oct; Vol. 6, pp. 1656-1665.
DOI:	10.1200/GO.20.00307
Abstrakt:	Purpose: Few studies have explored the relationship between body habitus and breast cancer outcomes in Caribbean women of African ancestry. This study evaluates the association between body mass index (BMI) and disease-free survival (DFS) in a retrospective cohort of 224 female Haitian patients with nonmetastatic breast cancer. Patients and Methods: BMI was obtained from the medical records and categorized as normal weight (< 25 kg/m 2 ), overweight (25-29.9 kg/m 2 ), and obese (≥ 30 kg/m 2 ). DFS was defined as time from surgical resection to disease recurrence, death, or censoring. Kaplan-Meier survival curves were generated, and the association between BMI and DFS was evaluated using Cox proportional hazard models to control for multiple confounders. Exploratory analyses were conducted on weight changes during adjuvant chemotherapy. Results: Eighty-three patients (37.1%) were normal weight, 66 (29.5%) were overweight, and 75 (33.5%) were obese. There were no statistical differences in baseline characteristics or treatments received by BMI group. Twenty-six patients died and 73 had disease recurrence. Median DFS was 41.1 months. Kaplan-Meier estimates showed no significant DFS differences by BMI categories. After controlling for confounders, normal weight patients, when compared with overweight and obese patients, had adjusted hazard ratios of 0.85 (95% CI, 0.49 to 1.49) and 0.90 (95% CI, 0.52 to 1.55), respectively. Overall, mean weight loss of 2% of body weight was noted over the course of adjuvant chemotherapy. Patients who were postmenopausal ( P = .007) and obese ( P = .05) lost more weight than other groups. However, chemotherapy-related weight changes did not have an impact on DFS. Conclusion: Baseline BMI and weight changes during adjuvant chemotherapy did not have an impact on DFS in this cohort. Future prospective studies in similar Caribbean breast cancer cohorts are needed to verify study findings.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu